The Impact Of Rising Drug-Resistant Infections On The Antibiotic Resistance Market: A Key Catalyst Accelerating Antibiotic Resistance Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Antibiotic Resistance Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
There has been a significant expansion in the antibiotic resistance market size in past few years. The market, which is valued at $12.21 billion in 2024, is projected to increase to $12.89 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. The notable growth during the historical period can be due to factors such as a shortage of new antibiotics, improper and excessive use of antimicrobials in humans, livestock, and vegetation, heavily polluted waste emissions, low rates of vaccination, and the absence of diagnostic instruments.

Antibiotic Resistance Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the market size for antibiotic resistance is anticipated to see robust growth, reaching a value of $16.97 billion in 2029 with a compound annual growth rate (CAGR) of 7.1%. Various factors such as incomplete treatment courses, globalization and travel, inadequate infection prevention and control, self-medication, cross-species transmission, and high population density can explain the growth during the forecast period. Key trends shaping this period include advancements in drug delivery technology, worldwide collaboration for surveillance, the growing influence of artificial intelligence, and a surge in innovative treatments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/antibiotic-resistance-global-market-report

What Are the Drivers Transforming the Antibiotic Resistance Market?
The growth of the antibiotic-resistance market is anticipated to be driven by the rising incidence of drug-resistant infections. These infections, caused by resistant bacteria, are considerably harder, if not impossible, to treat. Drugs for antimicrobial resistance are utilized to counter various drug-resistant infections, enhancing antibiotic treatment results for both targeted and non-targeted pathogens. The improvement is subject to specific resistance mechanisms and the interaction structure of the microbiome community. For example, the UK Health Security Agency, a government-based agency in the UK, issued a report in November 2023, which indicated that about 58,224 individuals in England were presumed to have contracted an antibiotic-resistant infection in 2022. This figure represents a 4% increment from the 55,792 cases documented in 2021. Consequently, the increasing occurrence of drug-resistant infections is propelling the antibiotic resistance market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12131&type=smp

What Long-Term Trends Will Define the Future of the Antibiotic Resistance Market?
In the antibiotic resistance market, the trending focus is on product innovation. The emphasis of major businesses in this market is on developing unique and innovative products to solidify their market standing. An apt illustration of this trend occurred in January 2023, when Alkem Laboratories Limited, a pharmaceutical entity based in India, launched a groundbreaking antibiotic called Zidavi to combat multi-drug resistant (MDR) infections. The primary aim of this move was to ensure the availability, affordability, and easy access to treatments that can preserve the lives of critically ill patients. A unique amalgamation of ceftazidime and avibactam, Zidavi can address infections due to multi-drug resistant (MDR) gram-negative pathogens. The product is offered as a sterile powdered concentrate for infusion and reconstitution, and each single-dose vial comprises ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam. Apart from this, it also provides an effective substitute for treating severe intra-abdominal infections (IAIs) and hospital-acquired pneumonia (HAP) that are caused by meropenem and colistin.

Which Segments in the Antibiotic Resistance Market Offer the Most Profit Potential?
The antibiotic resistance market covered in this report is segmented -

1) By Drug Class: Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones, Other Drug Classes
2) By Pathogen: Staphylococcus Aureus, Staphylococcus Pneumonia, Neisseria Gonorrhoeae, Enterococcus Faecium, Escherichia Coli, Klebsiella Pneumonia, Shigella, Clostridium Difficile, Other Pathogens
3) By Disease Type: Urinary Tract Infection, Intra-Abdominal Infection, Blood Stream infections, Clostridium Difficile Infections, Other Disease Types
4) By Mechanism Of Action: Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Other Mechanism Of Actions
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End-users

Subsegments:
1) By Beta Lactam Antibiotics: Penicillins, Cephalosporins, Carbapenems, Monobactams
2) By Cephalosporins: First-generation, Second-generation, Third-generation, Fourth-generation
3) By Quinolones Antibiotics: Fluoroquinolones, Other Quinolones
4) By Macrolide Antibiotics: Erythromycin, Azithromycin, Clarithromycin
5) By Tetracyclines: Doxycycline, Minocycline, Tetracycline
6) By Oxazolidinones: Linezolid, Tedizolid
7) By Other Drug Classes: Glycopeptides, Lipopeptides, Streptogramins, Polymyxins

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12131&type=smp

Which Firms Dominate the Antibiotic Resistance Market by Market Share and Revenue in 2025?
Major companies operating in the antibiotic resistance market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., Thermo Fisher Scientific Inc, AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Bio-Rad Laboratories Inc, Eppendorf Corporation, Takara Bio Inc, Wockhardt Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc, Armata Pharmaceuticals Inc.

Which Regions Offer the Highest Growth Potential in the Antibiotic Resistance Market?
North America was the largest region in the antibiotic resistance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12131

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.